Comment | Published:

Evolution of academic–industry partnerships in cardiovascular research and development

The advent of ‘big data’ and modern analytics mandates a change of scale in every aspect of the biomedical enterprise. These forces are realigning academic medicine and traditional industrial partners, and also creating the context for an emerging new ecosystem for discovery, translation, care and implementation that promises to transform and integrate all these areas of endeavour.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Schwab, K. The fourth industrial revolution: what it means and how to respond. Foreign Affairs (2015).

  2. 2.

    MacRae, C. A., Roden, D. M. & Loscalzo, J. The future of cardiovascular therapeutics. Circulation 133, 2610–2617 (2016).

  3. 3.

    Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371, 2488–2498 (2014).

Download references


C.A.M. is funded by The Burroughs Wellcome Foundation, the NIH and by awards from the AHA, AstraZeneca, Quest Diagnostics and Verily Life Sciences.

Author information

Correspondence to Calum A. MacRae.

Ethics declarations

Competing interests

The author declares no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark